PE20140969A1 - Combinacion de analogos del glucagon acilados con analogos de insulina - Google Patents
Combinacion de analogos del glucagon acilados con analogos de insulinaInfo
- Publication number
- PE20140969A1 PE20140969A1 PE2013001533A PE2013001533A PE20140969A1 PE 20140969 A1 PE20140969 A1 PE 20140969A1 PE 2013001533 A PE2013001533 A PE 2013001533A PE 2013001533 A PE2013001533 A PE 2013001533A PE 20140969 A1 PE20140969 A1 PE 20140969A1
- Authority
- PE
- Peru
- Prior art keywords
- analogs
- arg
- combination
- leu
- ala
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical class C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
SE REFIERE A UNA COMBINACION DE ANALOGOS DEL GLUCAGON ACILADOS CON ANALOGOS DE INSULINA, QUE COMPRENDE UN COMPUESTO QUE TIENE LA FORMULA: R1-Z-R2, EN LA QUE R1 ES H, ALQUILO C1-C4, ACETILO, FORMILO, ENTRE OTROS; R2 ES OH, NH2; Z ES UN PEPTIDO QUE TIENE LA FORMULA: His-X2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-X12-Tyr-Leu-Asp-X16-X17-Ala-Ala-X20-X21-Phe-Val-X24-Trp-Leu-X27-X28-Ala-X30, DONDE X2 SE SELECCIONA DE Aib, Ser; X12 SE SELECCIONA DE Lys, Arg, Leu; X16 ES Arg; X17 ES Arg; X20 SE SELECCIONA DE Arg, His; X21 SE SELECCIONA DE Asp, Glu; X24 SE SELECCIONA DE Ala, X; X27 SE SELECCIONA DE Leu Y X; X28 SE SELECCIONA DE Arg, X; X30 ES X, EN LA QUE CADA RESTO X SE SELECCIONA DEL GRUPO DE Glu, Lys, Ser, Cys, ENTRE OTROS. DICHA COMBINACION DE COMPUESTOS ES UTIL EN PROCEDIMIENTO PARA PREVENIR EL AUMENTO DE PESO, REDUCIR LOS NIVELES DE LDL EN CIRCULACION, ENTRE OTROS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161434698P | 2011-01-20 | 2011-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140969A1 true PE20140969A1 (es) | 2014-07-24 |
Family
ID=45607302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013001533A PE20140969A1 (es) | 2011-01-20 | 2012-01-20 | Combinacion de analogos del glucagon acilados con analogos de insulina |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20140011733A1 (es) |
| EP (1) | EP2665487A1 (es) |
| JP (1) | JP2014504597A (es) |
| KR (1) | KR20140043709A (es) |
| CN (1) | CN103491975B (es) |
| AR (1) | AR085086A1 (es) |
| AU (1) | AU2012208349A1 (es) |
| BR (1) | BR112013018269A2 (es) |
| CA (1) | CA2824397A1 (es) |
| CL (1) | CL2013002085A1 (es) |
| CO (1) | CO6761400A2 (es) |
| EA (1) | EA201390796A1 (es) |
| MA (1) | MA34913B1 (es) |
| MX (1) | MX2013008005A (es) |
| PE (1) | PE20140969A1 (es) |
| PH (1) | PH12013501495A1 (es) |
| SG (1) | SG192038A1 (es) |
| TN (1) | TN2013000251A1 (es) |
| TW (1) | TW201247702A (es) |
| UY (1) | UY33872A (es) |
| WO (1) | WO2012098462A1 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5635530B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| KR20150116912A (ko) | 2008-12-15 | 2015-10-16 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| US8680049B2 (en) | 2008-12-15 | 2014-03-25 | Zealand Pharma A/S | Glucagon analogues |
| ES2439499T3 (es) | 2008-12-15 | 2014-01-23 | Zealand Pharma A/S | Análogos de glucagón |
| PT2454282E (pt) | 2009-07-13 | 2015-06-23 | Zealand Pharma As | Análogos de glucagão acilados |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| MA34383B1 (fr) | 2010-06-24 | 2013-07-03 | Zealand Pharma As | Analogues de glucagon |
| WO2013041678A1 (en) | 2011-09-23 | 2013-03-28 | Novo Nordisk A/S | Novel glucagon analogues |
| AR090937A1 (es) | 2012-05-03 | 2014-12-17 | Zealand Pharma As | Compuestos agonista duales de gip-glp-1 y metodos para usarlos |
| BR112015001451B1 (pt) | 2012-07-23 | 2022-03-29 | Zealand Pharma A/S | Composto, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um composto ou de seu sal ou solvato farmaceuticamente aceitável |
| TWI608013B (zh) * | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| WO2014158900A1 (en) | 2013-03-14 | 2014-10-02 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
| RU2683039C2 (ru) | 2013-04-18 | 2019-03-26 | Ново Нордиск А/С | Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения |
| US9988429B2 (en) * | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| MX368436B (es) | 2013-10-17 | 2019-10-03 | Zealand Pharma As | Analogos de glucagon acilados. |
| CA2929459C (en) | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| KR102310392B1 (ko) | 2013-11-06 | 2021-10-13 | 질랜드 파마 에이/에스 | 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물 |
| AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| MX369656B (es) | 2014-01-20 | 2019-11-15 | Hanmi Pharm Ind Co Ltd | Insulina de accion prolongada y uso de la misma. |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| JP2017525656A (ja) | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー／エス | 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト |
| JP6657230B2 (ja) | 2014-09-24 | 2020-03-04 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | インクレチン−インスリンコンジュゲート |
| ES2883345T3 (es) | 2014-10-29 | 2021-12-07 | Zealand Pharma As | Compuestos agonistas del GIP y métodos |
| PL3283507T3 (pl) | 2015-04-16 | 2020-05-18 | Zealand Pharma A/S | Acylowany analog glukagonu |
| UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| BR102015031283A2 (pt) * | 2015-12-14 | 2018-09-18 | Univ Rio De Janeiro | Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento |
| WO2017160669A1 (en) * | 2016-03-18 | 2017-09-21 | Merck Sharp & Dohme Corp. | Insulin-incretin conjugates |
| WO2017189342A1 (en) | 2016-04-26 | 2017-11-02 | Merck Sharp & Dohme Corp. | Insulin dimer-incretin conjugates |
| AU2017332408B2 (en) | 2016-09-23 | 2022-02-10 | Hanmi Pharm. Co., Ltd. | Insulin analogs with reduced affinity to insulin receptor and use thereof |
| AU2018239037B2 (en) | 2017-03-23 | 2022-05-26 | Hanmi Pharm. Co., Ltd. | Insulin analog complex with reduced affinity for insulin receptor and use thereof |
| KR20200078414A (ko) * | 2018-12-21 | 2020-07-01 | 한미약품 주식회사 | 인슐린 및 글루카곤을 포함하는 약학 조성물 |
| CA3186427A1 (en) * | 2020-06-11 | 2021-12-16 | Abvance Therapeutics Inc. | Systems, devices, compositions and methods for treating diabetes |
| JP2024543441A (ja) * | 2021-11-19 | 2024-11-21 | メッドシャイン ディスカバリー インコーポレイテッド | ステープルペプチド及びその使用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| DE69428134T2 (de) | 1993-09-17 | 2002-05-02 | Novo Nordisk A/S, Bagsvaerd | Acyliertes insulin |
| US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| US5461031A (en) | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| ES2283025T3 (es) | 1996-08-30 | 2007-10-16 | Novo Nordisk A/S | Derivados de glp-1.1. |
| ATE290014T1 (de) | 1996-09-09 | 2005-03-15 | Zealand Pharma As | Festphasen-peptidsynthese |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| HUP0200297A3 (en) | 1999-03-17 | 2002-09-30 | Novo Nordisk As | Method for acylating peptides and the glutaminic acid derivatives as acylating agents |
| AU2002346491A1 (en) | 2001-12-19 | 2003-07-09 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
| EP1545460A4 (en) | 2001-12-20 | 2005-11-16 | Lilly Co Eli | INSULIN MOLECULE WITH TEMPORARY EFFECT |
| DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| CA2518776A1 (en) | 2003-04-29 | 2004-11-11 | Eli Lilly And Company | Insulin analogs having protracted time action |
| WO2006134340A2 (en) | 2005-06-13 | 2006-12-21 | Imperial Innovations Limited | Oxyntomodulin analogues and their effects on feeding behaviour |
| WO2007081824A2 (en) | 2006-01-06 | 2007-07-19 | Case Western Reserve University | Fibrillation resistant proteins |
| AU2007221366B2 (en) | 2006-02-22 | 2012-08-23 | Msd Italia S.R.L. | Oxyntomodulin derivatives |
| WO2008043033A2 (en) | 2006-10-04 | 2008-04-10 | Case Western Reserve University | Fibrillation-resistant insulin and insulin analogues |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| EA017849B1 (ru) | 2007-02-15 | 2013-03-29 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Соагонисты глюкагоновых/glp-1-рецепторов |
| WO2008152403A1 (en) | 2007-06-15 | 2008-12-18 | Zealand Pharma A/S | Glucagon analogues |
| KR101656107B1 (ko) | 2007-11-20 | 2016-09-08 | 암브룩스, 인코포레이티드 | 변형된 인슐린 폴리펩티드 및 이의 용도 |
| DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| AU2009203809B2 (en) | 2008-01-09 | 2013-07-25 | Sanofi-Aventis Deutschland Gmbh | Novel insulin derivatives having an extremely delayed time-action profile |
| CN101970476B (zh) | 2008-01-09 | 2014-08-27 | 塞诺菲-安万特德国有限公司 | 具有超延迟时效特征的胰岛素衍生物 |
| WO2009129250A2 (en) | 2008-04-14 | 2009-10-22 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
| NZ588857A (en) | 2008-04-22 | 2012-07-27 | Univ Case Western Reserve | Isoform-specific insulin analogue for control blood sugar levels |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| PA8830501A1 (es) * | 2008-06-17 | 2010-07-27 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| US8450270B2 (en) | 2008-06-17 | 2013-05-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
| PL219335B1 (pl) | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
| MX2011001181A (es) | 2008-07-31 | 2011-04-05 | Univ Case Western Reserve | Insulina estabilizada con halogeno. |
| US8680049B2 (en) * | 2008-12-15 | 2014-03-25 | Zealand Pharma A/S | Glucagon analogues |
| ES2439499T3 (es) * | 2008-12-15 | 2014-01-23 | Zealand Pharma A/S | Análogos de glucagón |
| KR20150116912A (ko) * | 2008-12-15 | 2015-10-16 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| JP5635530B2 (ja) * | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| US8481485B2 (en) | 2008-12-19 | 2013-07-09 | Indiana University Research And Technology Corporation | Insulin analogs |
| AU2009335715B2 (en) | 2008-12-19 | 2016-09-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| CN101519446A (zh) | 2009-03-31 | 2009-09-02 | 上海一就生物医药有限公司 | 一种重组人胰岛素及其类似物的制备方法 |
| PT2454282E (pt) * | 2009-07-13 | 2015-06-23 | Zealand Pharma As | Análogos de glucagão acilados |
| BR112012027759A2 (pt) * | 2010-04-27 | 2017-08-15 | Zealand Pharma As | Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso |
| AR081975A1 (es) * | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
-
2012
- 2012-01-20 MX MX2013008005A patent/MX2013008005A/es not_active Application Discontinuation
- 2012-01-20 CN CN201280005920.1A patent/CN103491975B/zh not_active Expired - Fee Related
- 2012-01-20 CA CA2824397A patent/CA2824397A1/en not_active Abandoned
- 2012-01-20 PE PE2013001533A patent/PE20140969A1/es not_active Application Discontinuation
- 2012-01-20 EP EP12704117.6A patent/EP2665487A1/en not_active Withdrawn
- 2012-01-20 UY UY0001033872A patent/UY33872A/es not_active Application Discontinuation
- 2012-01-20 AU AU2012208349A patent/AU2012208349A1/en not_active Abandoned
- 2012-01-20 AR ARP120100195A patent/AR085086A1/es unknown
- 2012-01-20 KR KR1020137018388A patent/KR20140043709A/ko not_active Withdrawn
- 2012-01-20 MA MA36191A patent/MA34913B1/fr unknown
- 2012-01-20 SG SG2013055090A patent/SG192038A1/en unknown
- 2012-01-20 EA EA201390796A patent/EA201390796A1/ru unknown
- 2012-01-20 BR BR112013018269A patent/BR112013018269A2/pt not_active IP Right Cessation
- 2012-01-20 PH PH1/2013/501495A patent/PH12013501495A1/en unknown
- 2012-01-20 US US13/980,087 patent/US20140011733A1/en not_active Abandoned
- 2012-01-20 TW TW101102724A patent/TW201247702A/zh unknown
- 2012-01-20 WO PCT/IB2012/000134 patent/WO2012098462A1/en not_active Ceased
- 2012-01-20 JP JP2013549906A patent/JP2014504597A/ja active Pending
-
2013
- 2013-06-11 TN TNP2013000251A patent/TN2013000251A1/fr unknown
- 2013-07-11 CO CO13165262A patent/CO6761400A2/es unknown
- 2013-07-19 CL CL2013002085A patent/CL2013002085A1/es unknown
-
2015
- 2015-09-17 US US14/857,067 patent/US20160000883A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ612719A (en) | 2015-05-29 |
| TN2013000251A1 (en) | 2014-11-10 |
| CA2824397A1 (en) | 2012-07-26 |
| CN103491975A (zh) | 2014-01-01 |
| CO6761400A2 (es) | 2013-09-30 |
| SG192038A1 (en) | 2013-08-30 |
| EP2665487A1 (en) | 2013-11-27 |
| US20160000883A1 (en) | 2016-01-07 |
| US20140011733A1 (en) | 2014-01-09 |
| AU2012208349A1 (en) | 2013-07-18 |
| CL2013002085A1 (es) | 2013-12-06 |
| UY33872A (es) | 2012-08-31 |
| JP2014504597A (ja) | 2014-02-24 |
| KR20140043709A (ko) | 2014-04-10 |
| BR112013018269A2 (pt) | 2017-06-06 |
| AR085086A1 (es) | 2013-09-11 |
| PH12013501495A1 (en) | 2013-09-16 |
| MA34913B1 (fr) | 2014-02-01 |
| TW201247702A (en) | 2012-12-01 |
| EA201390796A1 (ru) | 2014-07-30 |
| MX2013008005A (es) | 2013-08-21 |
| WO2012098462A1 (en) | 2012-07-26 |
| CN103491975B (zh) | 2016-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140969A1 (es) | Combinacion de analogos del glucagon acilados con analogos de insulina | |
| MX2019008148A (es) | Uso de peptidos glp-1 de accion prolongada. | |
| ECSP14028506A (es) | Nucleósidos de espirooxetano de uracilo | |
| CY1116987T1 (el) | Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις | |
| PE20150900A1 (es) | Derivados de exendida-4 como agonistas duales de glp1/glucagon | |
| BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
| ECSP11011390A (es) | Compuestos espiro-amidas sustituidas | |
| DOP2014000115A (es) | Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| ECSP13012519A (es) | Compuestos sustituidos de benzamida | |
| EA201490070A1 (ru) | Коантагонисты глюкагонового рецептора/glp-1-рецептора | |
| PE20151239A1 (es) | Derivados de exendina-4 funcionalizada | |
| NI201200013A (es) | Composición de insulina de acción prolongada | |
| PE20121130A1 (es) | Analogos de glucagon acilados | |
| AR091837A1 (es) | Compuestos para inmunoterapia dirigida | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| CL2012003226A1 (es) | Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas. | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| CL2014003421A1 (es) | Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad. | |
| EA201490037A1 (ru) | Антагонисты trpv4 | |
| GT201300186A (es) | Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9 | |
| EA201691216A1 (ru) | Композиции линаклотида с замедленным высвобождением | |
| EA201400537A1 (ru) | 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА | |
| AR081819A1 (es) | Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades | |
| EA201590364A1 (ru) | Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда | |
| CL2017000293A1 (es) | Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |